Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20898565 | 0.83 | IDO1 (0.75) | IDO1 | |
| SCHEMBL20905667 | 0.82 | IDO1 (0.70) | IDO1CYP2C9 | |
| SCHEMBL20898571 | 0.74 | IDO1 (0.50) | IDO1CYP2C9SMN1; SMN2 | |
| SCHEMBL26000953 | 0.74 | IDO1 (0.69) | IDO1CYP2C9SMN1; SMN2 | |
| SCHEMBL20905265 | 0.74 | IDO1 (0.56) | IDO1CYP2C9SMN1; SMN2 | |
| SCHEMBL29631477 | 0.72 | IDO1 (1.00) | IDO1 | |
| SCHEMBL20899519 | 0.72 | IDO1 (1.00) | IDO1 | |
| SCHEMBL20898568 | 0.70 | IDO1 (0.80) | IDO1SMN1; SMN2 | |
| SCHEMBL29631425 | 0.70 | IDO1 (0.80) | IDO1SMN1; SMN2 | |
| SCHEMBL31492746 | 0.68 | IDO1 (0.78) | IDO1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319295-B2 | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200239423-A1 | NOVEL SUBSTITUTED PHENYLOXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239423-A1 | NOVEL SUBSTITUTED PHENYLOXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 795/4885SMN1; SMN2 2054/4885 |
| US-11319295-B2 | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 603/4885SMN1; SMN2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.